John Robert Springer

TL;DR: In this Letter, the structure-activity relationships, optimization of design, testing criteria, and human half-life data for a series of selective COX-2 inhibitors are provided.

TL;DR: A novel series of orally active, selective benzoxazole piperidinecarboxamides as mPGES-1 inhibitors is discovered, including 23, 26, and 29, which were effective in a carrageenan-stimulated guinea pig air pouch model of inflammation.

TL;DR: In this article, the authors present compounds that form covalent bonds with Bruton's tyrosine kinase (BTK) for the treatment of autoimmune diseases or conditions.

TL;DR: The design, synthesis, mPGES-1 activity and in vivo PK of a novel set of substituted benzoxazoles are described and a conformation-based hypothesis for mPGE(2) synthase1 activity based on the preferred conformation of the cyclohexane ring within this class of inhibitors is described.

TL;DR: The subject of as discussed by the authors concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders, and the compounds of particular interest are benzopyrans and their analogs defined by formula (1).